320 related articles for article (PubMed ID: 22357272)
1. Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells.
Murata T; Kondo Y; Sugimoto A; Kawashima D; Saito S; Isomura H; Kanda T; Tsurumi T
J Virol; 2012 May; 86(9):4752-61. PubMed ID: 22357272
[TBL] [Abstract][Full Text] [Related]
2. Histone hyperacetylation occurs on promoters of lytic cycle regulatory genes in Epstein-Barr virus-infected cell lines which are refractory to disruption of latency by histone deacetylase inhibitors.
Countryman JK; Gradoville L; Miller G
J Virol; 2008 May; 82(10):4706-19. PubMed ID: 18337569
[TBL] [Abstract][Full Text] [Related]
3. Role of the histone H3 lysine 9 methyltransferase Suv39 h1 in maintaining Epsteinn-Barr virus latency in B95-8 cells.
Imai K; Kamio N; Cueno ME; Saito Y; Inoue H; Saito I; Ochiai K
FEBS J; 2014 May; 281(9):2148-58. PubMed ID: 24588869
[TBL] [Abstract][Full Text] [Related]
4. Switching of EBV cycles between latent and lytic states.
Murata T; Tsurumi T
Rev Med Virol; 2014 May; 24(3):142-53. PubMed ID: 24339346
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Epstein-Barr virus reactivation from latency.
Murata T
Microbiol Immunol; 2014 Jun; 58(6):307-17. PubMed ID: 24786491
[TBL] [Abstract][Full Text] [Related]
6. The chemopreventive compound curcumin is an efficient inhibitor of Epstein-Barr virus BZLF1 transcription in Raji DR-LUC cells.
Hergenhahn M; Soto U; Weninger A; Polack A; Hsu CH; Cheng AL; Rösl F
Mol Carcinog; 2002 Mar; 33(3):137-45. PubMed ID: 11870879
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2.
Friedman J; Cho WK; Chu CK; Keedy KS; Archin NM; Margolis DM; Karn J
J Virol; 2011 Sep; 85(17):9078-89. PubMed ID: 21715480
[TBL] [Abstract][Full Text] [Related]
8. A role for the nucleosome assembly proteins TAF-Iβ and NAP1 in the activation of BZLF1 expression and Epstein-Barr virus reactivation.
Mansouri S; Wang S; Frappier L
PLoS One; 2013; 8(5):e63802. PubMed ID: 23691099
[TBL] [Abstract][Full Text] [Related]
9. BZLF1 governs CpG-methylated chromatin of Epstein-Barr Virus reversing epigenetic repression.
Woellmer A; Arteaga-Salas JM; Hammerschmidt W
PLoS Pathog; 2012 Sep; 8(9):e1002902. PubMed ID: 22969425
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic modification of the Epstein-Barr virus BZLF1 promoter regulates viral reactivation from latency.
Murata T; Tsurumi T
Front Genet; 2013; 4():53. PubMed ID: 23577022
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle.
Gradoville L; Kwa D; El-Guindy A; Miller G
J Virol; 2002 Jun; 76(11):5612-26. PubMed ID: 11991990
[TBL] [Abstract][Full Text] [Related]
12. Transforming growth factor beta 1 stimulates expression of the Epstein-Barr virus BZLF1 immediate-early gene product ZEBRA by an indirect mechanism which requires the MAPK kinase pathway.
Fahmi H; Cochet C; Hmama Z; Opolon P; Joab I
J Virol; 2000 Jul; 74(13):5810-8. PubMed ID: 10846060
[TBL] [Abstract][Full Text] [Related]
13. De novo protein synthesis is required for lytic cycle reactivation of Epstein-Barr virus, but not Kaposi's sarcoma-associated herpesvirus, in response to histone deacetylase inhibitors and protein kinase C agonists.
Ye J; Gradoville L; Daigle D; Miller G
J Virol; 2007 Sep; 81(17):9279-91. PubMed ID: 17596302
[TBL] [Abstract][Full Text] [Related]
14. HCF1 and OCT2 Cooperate with EBNA1 To Enhance OriP-Dependent Transcription and Episome Maintenance of Latent Epstein-Barr Virus.
Dheekollu J; Wiedmer A; Sentana-Lledo D; Cassel J; Messick T; Lieberman PM
J Virol; 2016 Jun; 90(11):5353-5367. PubMed ID: 27009953
[TBL] [Abstract][Full Text] [Related]
15. Signal Transduction and Transcription Factor Modification during Reactivation of Epstein-Barr Virus from Latency.
Bryant H; Farrell PJ
J Virol; 2002 Oct; 76(20):10290-8. PubMed ID: 12239305
[TBL] [Abstract][Full Text] [Related]
16. Histone acetylation and reactivation of Epstein-Barr virus from latency.
Jenkins PJ; Binné UK; Farrell PJ
J Virol; 2000 Jan; 74(2):710-20. PubMed ID: 10623733
[TBL] [Abstract][Full Text] [Related]
17. TORC2, a coactivator of cAMP-response element-binding protein, promotes Epstein-Barr virus reactivation from latency through interaction with viral BZLF1 protein.
Murata T; Sato Y; Nakayama S; Kudoh A; Iwahori S; Isomura H; Tajima M; Hishiki T; Ohshima T; Hijikata M; Shimotohno K; Tsurumi T
J Biol Chem; 2009 Mar; 284(12):8033-41. PubMed ID: 19164291
[TBL] [Abstract][Full Text] [Related]
18. Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim.
Paschos K; Smith P; Anderton E; Middeldorp JM; White RE; Allday MJ
PLoS Pathog; 2009 Jun; 5(6):e1000492. PubMed ID: 19557159
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel element involved in regulation of the lytic switch BZLF1 gene promoter of Epstein-Barr virus.
Kraus RJ; Mirocha SJ; Stephany HM; Puchalski JR; Mertz JE
J Virol; 2001 Jan; 75(2):867-77. PubMed ID: 11134300
[TBL] [Abstract][Full Text] [Related]
20. Contribution of myocyte enhancer factor 2 family transcription factors to BZLF1 expression in Epstein-Barr virus reactivation from latency.
Murata T; Narita Y; Sugimoto A; Kawashima D; Kanda T; Tsurumi T
J Virol; 2013 Sep; 87(18):10148-62. PubMed ID: 23843637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]